Immix Biopharma, Inc. Expected to Post Q2 2024 Earnings of ($0.21) Per Share (NASDAQ:IMMX)

Immix Biopharma, Inc. (NASDAQ:IMMX) – HC Wainwright issued their Q2 2024 earnings estimates for Immix Biopharma in a report issued on Monday, July 1st. HC Wainwright analyst R. Burns forecasts that the company will post earnings of ($0.21) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Immix Biopharma’s current full-year earnings is ($0.93) per share. HC Wainwright also issued estimates for Immix Biopharma’s Q3 2024 earnings at ($0.21) EPS, Q4 2024 earnings at ($0.19) EPS, FY2024 earnings at ($0.83) EPS, Q1 2025 earnings at ($0.17) EPS, Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.15) EPS and FY2025 earnings at ($0.67) EPS.

Immix Biopharma (NASDAQ:IMMX) last released its earnings results on Thursday, May 9th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.01.

Immix Biopharma Stock Performance

IMMX stock opened at $2.45 on Wednesday. Immix Biopharma has a one year low of $1.55 and a one year high of $7.75. The company’s fifty day moving average price is $2.16 and its 200-day moving average price is $3.35. The company has a market capitalization of $64.71 million, a PE ratio of -2.63 and a beta of 0.17.

Institutional Investors Weigh In On Immix Biopharma

Large investors have recently bought and sold shares of the business. Private Advisor Group LLC bought a new stake in Immix Biopharma in the fourth quarter worth $690,000. Jump Financial LLC bought a new stake in Immix Biopharma in the fourth quarter worth $128,000. Imprint Wealth LLC increased its position in Immix Biopharma by 49.4% in the fourth quarter. Imprint Wealth LLC now owns 34,483 shares of the company’s stock worth $239,000 after purchasing an additional 11,400 shares during the last quarter. OLD National Bancorp IN bought a new stake in Immix Biopharma in the fourth quarter worth $69,000. Finally, Tocqueville Asset Management L.P. increased its position in Immix Biopharma by 89.0% in the first quarter. Tocqueville Asset Management L.P. now owns 37,800 shares of the company’s stock worth $116,000 after purchasing an additional 17,800 shares during the last quarter. Institutional investors own 11.26% of the company’s stock.

Immix Biopharma Company Profile

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.